Menu Search
Equities

Proteome Sciences PLC

PRM:DEU

Proteome Sciences PLC

Actions
  • Price (EUR)0.048
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+23.08%
  • Beta--
Data delayed at least 15 minutes, as of May 09 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Proteome Sciences plc is a specialist provider of contract proteomics services. The Company’s services enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic and therapeutic applications. SysQuant and TMT MS2 are unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents for multiplex quantitative proteomics.

  • Revenue in GBP (TTM)5.03m
  • Net income in GBP-2.44m
  • Incorporated1993
  • Employees35.00
  • Location
    Proteome Sciences PLCCoveham House, Downside Bridge RoadADDLESTONE KT11 3EPUnited KingdomGBR
  • Phone+44 207 043 2116
  • Fax+44 203 637 7516
  • Websitehttps://www.proteomics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.